Search Bar & Filters
Found 49 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating two different pacing methods for patients with slow heart rates, called bradycardia. This study compares the common right ventricular pacing approach with a newer physiological pacing method that includes His bundle and left bundle area pacing. The trial aims to better understand how these pacing techniques affect patient outcomes, including mortality and heart failure morbidity, in a large group of 2600 patients. Participants will receive a pacemaker implant and be randomly assigned to either right ventricular pacing or physiological pacing. The physiological pacing may involve His bundle pacing or left bundle pacing, but if these are not successful, biventricular pacing will be used. A subgroup of 500 participants will take part in an optional echocardiographic sub-study to assess heart function changes over a 24-month period. Throughout the study, patients will be assessed at baseline and every six months after randomization, with follow-up lasting up to 78 months. Researchers will monitor outcomes such as mortality, heart failure events, device-related safety issues, patient quality of life, symptoms, and pacemaker-derived data like arrhythmias and activity levels. The echocardiographic sub-study will measure specific heart function changes to understand pacing-induced cardiomyopathy. Participants involvement includes implantation, regular follow-up visits, questionnaires, and optional imaging assessments.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are studying patients with cirrhosis caused by alcohol-related or metabolic dysfunction-associated steatotic liver disease MASLD. The trial aims to evaluate whether taking capsules containing faecal microbiota from healthy donors can reduce infections and mortality in these patients. This Phase 3 trial follows earlier research that showed faecal microbiota transplantation FMT delivered via endoscopy was safe and feasible, leading to the development of capsules for easier treatment administration. Participants will be randomly assigned to receive either encapsulated FMT or placebo capsules that look identical but contain no active treatment. They will take five capsules every three months over a total period of 21 months or until they develop an infection requiring hospital admission. This double-blind trial means neither participants nor study staff will know which treatment is given. The study will last up to 24 months including follow-up, monitoring effects on infection rates, liver health, immune system function, and antibiotic resistance. Throughout the trial, participants will be regularly assessed for infections, liver disease progression, hospital admissions, quality of life, mental health, alcohol use, and safety of FMT treatment. Laboratory tests will examine immune response and bacterial resistance. The primary outcome is the time until first infection needing hospital care. The study involves detailed monitoring and follow-up visits for up to two years to understand the treatments impact and safety in patients with cirrhosis.
Actively Recruiting
Researchers are evaluating whether less frequent dosing of pembrolizumab after six months of standard treatment is safe and effective for patients with advanced non-small cell lung cancer NSCLC. Pembrolizumab, an immunotherapy targeting the PD-1 receptor, has improved outcomes in NSCLC, but current dosing every six weeks for up to two years may result in overtreatment. This UK phase III trial aims to find if reducing dose frequency can maintain effectiveness while improving quality of life and lowering costs. Participants who have received six months of pembrolizumab, with or without chemotherapy, and plan to continue treatment will be randomized to receive pembrolizumab intravenously every six weeks control or every twelve weeks initially. If the 12-week dosing is found to be not less effective, additional groups receiving doses every nine, fifteen, and eighteen weeks will be included. Patients who experience disease progression while on reduced frequency dosing can return to the standard six-week schedule. Throughout the study, participants will be monitored for overall survival at 18 months from randomization, along with other outcomes such as progression-free survival, response rate, duration of response, and adverse events over two years. The study involves regular hospital visits for treatment and assessments, and the results may lead to safer, more convenient treatment options for NSCLC patients. The total participation time varies depending on individual treatment and follow-up schedules.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tacabrutideg compared with investigators choice treatments in people with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have previously been treated with both Bruton Tyrosine Kinase inhibitors BTKi and B-cell LeukemiaLymphoma 2 protein inhibitors BCL2i. This study aims to compare how long participants live without their disease worsening under these treatments. The study is a Phase 3, randomized trial sponsored by BeOne Medicines. Participants will be randomly assigned to receive either tacabrutideg taken orally once daily until treatment discontinuation criteria are met, or investigators choice of treatment. The investigators choice includes combinations such as idelalisib plus rituximab for CLL only, bendamustine plus rituximab, or venetoclax plus rituximab retreatment. Some of these drugs are administered orally while others are given intravenously. During the study, participants will be closely monitored for progression-free survival over approximately 36 months, along with overall survival and response rates. Researchers will assess quality of life using specific questionnaires for up to 24 months, and track treatment-emergent adverse events. The study involves regular assessments and evaluations to understand treatment effects and safety over the course of participation, which may last several years until study completion in 2030.
Actively Recruiting
Researchers are evaluating the combined use of finerenone and empagliflozin compared to usual care to assess their safety and effectiveness in patients hospitalized with heart failure. This international, randomized, controlled, open-label trial aims to study an early, intensive management approach for heart failure treatment. Participants will be assigned to receive either the combination of oral finerenone plus oral empagliflozin or usual care. The study focuses on treatment during hospitalization and shortly after, comparing these approaches to understand the clinical benefits and risks over a six-month period. During the trial, participants will be monitored for clinical outcomes including serious adverse events and events leading to treatment discontinuation. Researchers will measure heart failure events, symptom changes using the Kansas City Cardiomyopathy Questionnaire, and overall survival up to six months. Safety and efficacy data will be collected throughout the study period ending in November 2027.
Actively Recruiting
Researchers are comparing the effectiveness and safety of sonrotoclax combined with either obinutuzumab or rituximab against venetoclax combined with rituximab in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This phase 3 study aims to assess progression-free survival and other important outcomes among these treatment combinations to find better options for patients. Participants will be randomly assigned to one of four treatment groups sonrotoclax plus obinutuzumab, sonrotoclax plus rituximab, sonrotoclax plus obinutuzumab guided by minimal residual disease evaluation, or venetoclax plus rituximab. Sonrotoclax and venetoclax are given orally, while obinutuzumab and rituximab are given intravenously. The study includes detailed treatment schedules and monitoring of minimal residual disease in one group. During the study, participants will have regular evaluations including assessments by blinded independent review committees of progression-free survival, response rates, and overall survival. Quality of life and symptom burden will also be measured using specific questionnaires. Safety will be monitored from the first dose through follow-up periods lasting up to several years. The total study duration extends to approximately six years, with ongoing assessments to understand treatment effects and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of two fixed-duration drug combinations for adults with previously untreated chronic lymphocytic leukemia CLL. This Phase 3 study compares sonrotoclax plus zanubrutinib against venetoclax plus acalabrutinib to see which therapy better controls the disease. The trial is sponsored by BeOne Medicines and focuses on treatment outcomes in this patient group. Participants receive either sonrotoclax and zanubrutinib or venetoclax and acalabrutinib, both given orally for a set period. After completing the drug regimen, participants enter an observation phase to monitor their health and disease status. The study uses a randomized, parallel design without masking, meaning participants are assigned to one of two treatment groups openly. During the trial, participants undergo regular assessments including imaging to measure disease size, evaluations of bone marrow and organ function, and monitoring for side effects. The primary outcomes include progression-free survival monitored for up to about 70 months and rates of undetectable minimal residual disease measured up to approximately 16 months. Secondary outcomes cover response rates, overall survival, adverse events, and quality of life scores. The total study duration extends to late 2031, allowing long-term follow-up and safety evaluation.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of sonrotoclax combined with zanubrutinib compared to zanubrutinib with placebo in adults who have relapsed or refractory mantle cell lymphoma MCL, a rare and aggressive blood cancer. The study focuses on whether the combination of sonrotoclax and zanubrutinib can better control the disease and improve patient outcomes. Participants will be randomly assigned to one of two groups one receiving sonrotoclax plus zanubrutinib, and the other receiving zanubrutinib plus a placebo. All treatments are taken orally. The placebo is a pill without active medicine. The study design is double-blind, so neither participants nor doctors know which treatment is given during the trial unless medically necessary. The study will last up to approximately 7 years. During this time, participants will visit clinics regularly for treatment, health assessments, blood tests, and tumor imaging. Researchers will measure how long participants live without disease worsening, overall survival, response rates, quality of life, and safety through side effect monitoring. These evaluations will help understand the treatments impact on the disease and patient wellbeing.
Actively Recruiting
Researchers are evaluating the study medicine elranatamab, alone and combined with daratumumab, in people with multiple myeloma who have previously been treated with therapies including lenalidomide. The trial aims to determine whether elranatamab offers more benefit compared to a combination therapy of daratumumab, pomalidomide, and dexamethasone, while also assessing the safety and activity of elranatamab with daratumumab. This is a Phase 3, randomized, open-label study designed to compare these treatment options and to evaluate infection protection measures. The study includes three parts. Part 1 tests the safety and activity of different doses of elranatamab combined with daratumumab. In Part 2, participants are randomly assigned to receive elranatamab alone, elranatamab plus daratumumab, or the combination of daratumumab, pomalidomide, and dexamethasone. Part 3 assesses the impact of enhanced infection protection in participants receiving elranatamab alone or with daratumumab. Treatments are administered subcutaneously or orally as appropriate, and participants continue treatment until disease progression, unacceptable side effects, or withdrawal. Participants will undergo regular assessments including monitoring of disease progression, safety evaluations, and adverse event tracking. Key outcome measures include dose-limiting toxicities, progression-free survival, and treatment-emergent adverse events. Other evaluations include overall survival, response rates, duration of response, pharmacokinetics, immunogenicity, and quality of life assessments. Follow-up and monitoring continue for up to 51 months after randomization to capture long-term effects and safety.
1-10 of 49
1